Urovant Sciences (NASDAQ:UROV) Given a $28.00 Price Target by HC Wainwright Analysts

Urovant Sciences (NASDAQ:UROV) received a $28.00 price objective from investment analysts at HC Wainwright in a research report issued on Monday, TipRanks reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 198.51% from the stock’s current price.

Separately, ValuEngine raised Urovant Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $21.44.

Urovant Sciences stock traded down $0.07 during midday trading on Monday, reaching $9.38. The company’s stock had a trading volume of 27,800 shares, compared to its average volume of 51,997. The stock’s 50-day simple moving average is $9.63 and its 200-day simple moving average is $8.53. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.20 and a quick ratio of 6.20. Urovant Sciences has a 52-week low of $4.05 and a 52-week high of $14.49. The stock has a market capitalization of $289.14 million and a P/E ratio of -2.12.

Urovant Sciences (NASDAQ:UROV) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.02). As a group, equities research analysts expect that Urovant Sciences will post -4.02 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. LVW Advisors LLC purchased a new stake in Urovant Sciences in the third quarter valued at $372,000. Atria Investments LLC purchased a new stake in Urovant Sciences in the second quarter valued at $3,420,000. Perceptive Advisors LLC raised its position in Urovant Sciences by 116.7% in the second quarter. Perceptive Advisors LLC now owns 1,875,426 shares of the company’s stock valued at $14,835,000 after purchasing an additional 1,010,067 shares during the period. Sio Capital Management LLC raised its position in Urovant Sciences by 2.3% in the second quarter. Sio Capital Management LLC now owns 220,042 shares of the company’s stock valued at $1,741,000 after purchasing an additional 5,000 shares during the period. Finally, Vanguard Group Inc. raised its position in Urovant Sciences by 7.3% in the second quarter. Vanguard Group Inc. now owns 131,487 shares of the company’s stock valued at $1,040,000 after purchasing an additional 9,000 shares during the period. Institutional investors own 24.10% of the company’s stock.

About Urovant Sciences

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

See Also: Roth IRA

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.